Roderick Macdonald

Roderick Macdonald's AcademicInfluence.com Rankings

Roderick Macdonald

Law

#2793

World Rank

#3472

Historical Rank

International Law

#795

World Rank

#969

Historical Rank

law Degrees

Roderick Macdonald

Philosophy

#9471

World Rank

#13035

Historical Rank

Logic

#6444

World Rank

#7961

Historical Rank

philosophy Degrees

Download Badge

Law
Philosophy

Roderick Macdonald's Degrees

Doctorate Medicine McGill University

Why Is Roderick Macdonald Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roderick Macdonald's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society (2011) (981)
Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer (2008) (603)
Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. (1998) (388)
Teledermatology for diagnosis and management of skin conditions: a systematic review. (2011) (285)
Effectiveness of statin therapy in adults with coronary heart disease. (2004) (276)
Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis (2009) (272)
Phytoestrogens for Treatment of Menopausal Symptoms: A Systematic Review (2004) (264)
Prevalence, Assessment, and Treatment of Mild Traumatic Brain Injury and Posttraumatic Stress Disorder: A Systematic Review of the Evidence (2011) (262)
Medical Management to Prevent Recurrent Nephrolithiasis in Adults: A Systematic Review for an American College of Physicians Clinical Guideline (2013) (255)
Systematic Review: Effective Management Strategies for Lactose Intolerance (2010) (221)
Antimicrobial Stewardship in Outpatient Settings: A Systematic Review (2014) (218)
Serenoa repens for benign prostatic hyperplasia. (2000) (197)
Chondroitin for osteoarthritis. (2015) (196)
Meta-analysis: Effect of Patient Self-testing and Self-management of Long-Term Anticoagulation on Major Clinical Outcomes (2011) (196)
Phytotherapy for benign prostatic hyperplasia (2000) (181)
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. (2001) (177)
Advanced Wound Care Therapies for Nonhealing Diabetic, Venous, and Arterial Ulcers (2013) (174)
Fecal Microbiota Transplantation for Clostridium difficile Infection (2015) (174)
Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians (2016) (168)
Serenoa repens for benign prostatic hyperplasia. (2012) (163)
Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. (2009) (163)
Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline (2012) (161)
Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline (2011) (159)
Antimicrobial Stewardship Programs in Inpatient Hospital Settings: A Systematic Review (2014) (142)
Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline (2007) (128)
Lactose intolerance and health. (2010) (126)
Comparative Effectiveness of Clostridium difficile Treatments (2011) (122)
Antiviral Therapy for Adults With Chronic Hepatitis B: A Systematic Review for a National Institutes of Health Consensus Development Conference (2009) (114)
Association between hospital and surgeon radical prostatectomy volume and patient outcomes: a systematic review. (2008) (114)
Diagnosis and Treatment of Chronic Abacterial Prostatitis (2000) (113)
Beta-sitosterols for benign prostatic hyperplasia. (1999) (113)
Systematic Review: Repair of Unruptured Abdominal Aortic Aneurysm (2007) (111)
Antibiotic prophylaxis for transurethral prostatic resection in men with preoperative urine containing less than 100,000 bacteria per ml: a systematic review. (2005) (109)
Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. (2000) (104)
Pharmacist-Led Chronic Disease Management: A Systematic Review of Effectiveness and Harms Compared With Usual Care (2016) (102)
Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians (2016) (102)
Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness (2007) (101)
Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review (2012) (99)
Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline. (2012) (97)
Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. (2003) (96)
Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer (2008) (91)
Comparison of endovascular and open surgical repairs for abdominal aortic aneurysm. (2006) (90)
A systematic review of Cernilton for the treatment of benign prostatic hyperplasia (2000) (89)
Medical and endoscopic therapies for angiodysplasia and gastric antral vascular ectasia: a systematic review. (2014) (79)
Evidence Report/Technology Assessment (2003) (77)
Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. (2005) (76)
Laser prostatectomy for benign prostatic obstruction. (2000) (76)
Effects on Health Outcomes of a Mediterranean Diet With No Restriction on Fat Intake (2016) (73)
Enhanced Recovery Protocols for Adults Undergoing Colorectal Surgery: A Systematic Review and Meta-analysis (2018) (73)
Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. (2002) (72)
Microwave thermotherapy for benign prostatic hyperplasia. (2012) (71)
Diagnosis and treatment of chronic abacterial prostatitis: a systematic review. (2000) (71)
Pharmacologic therapy for primary restless legs syndrome: a systematic review and meta-analysis. (2013) (68)
Couple and family involvement in adult mental health treatment: a systematic review. (2013) (65)
Spirometry as a motivational tool to improve smoking cessation rates: a systematic review of the literature. (2007) (64)
Microwave thermotherapy for benign prostatic hyperplasia. (2007) (63)
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention (2019) (62)
Delirium: Screening, Prevention, and Diagnosis – A Systematic Review of the Evidence (2011) (62)
Remdesivir for Adults With COVID-19 (2020) (62)
Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes - A Systematic Review of the Evidence (2012) (61)
Finasteride for benign prostatic hyperplasia. (2010) (61)
Five-alpha-reductase Inhibitors for prostate cancer prevention. (2008) (61)
Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points (2022) (61)
Multidisciplinary Postacute Rehabilitation for Moderate to Severe Traumatic Brain Injury in Adults (2012) (61)
Participation after multidisciplinary rehabilitation for moderate to severe traumatic brain injury in adults: a systematic review. (2013) (61)
Trazodone for erectile dysfunction: a systematic review and meta‐analysis (2003) (60)
Timing of dialysis initiation, duration and frequency of hemodialysis sessions, and membrane flux: a systematic review for a KDOQI clinical practice guideline. (2015) (56)
An Evidence Map of the Women Veterans’ Health Research Literature (2008–2015) (2017) (55)
Neurotoxin Treatments for Urinary Incontinence in Subjects With Spinal Cord Injury or Multiple Sclerosis: A Systematic Review of Effectiveness and Adverse Effects (2008) (54)
Endoscopic and Medical Therapy for Chronic Radiation Proctopathy: A Systematic Review (2012) (53)
Transurethral microwave thermotherapy vs transurethral resection for treating benign prostatic hyperplasia: a systematic review (2004) (51)
Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. (2017) (50)
5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review (2010) (48)
Screening Pelvic Examinations in Asymptomatic, Average-Risk Adult Women: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians (2014) (47)
Carbohydrate and lipid disorders and relevant considerations in persons with spinal cord injury. (2008) (46)
Deprescribing for Community-Dwelling Older Adults: a Systematic Review and Meta-analysis (2020) (44)
Effectiveness of Family and Caregiver Interventions on Patient Outcomes in Adults with Cancer: A Systematic Review (2014) (43)
Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects (2004) (42)
Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. (2009) (41)
Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. (2017) (40)
Intermediate- and Long-Term Cognitive Outcomes After Cardiovascular Procedures in Older Adults (2015) (39)
Terazosin for benign prostatic hyperplasia. (1994) (38)
Clinical Efficacy of OM-85 BV in COPD and Chronic Bronchitis: A Systematic Review (2005) (37)
The Assessment and Treatment of Individuals with History of Traumatic Brain Injury and Post-Traumatic Stress Disorder: A Systematic Review of the Evidence (2009) (37)
Major Update: Remdesivir for Adults With COVID-19 (2021) (35)
Cost-effectiveness of abdominal aortic aneurysm repair: A systematic review (2007) (31)
Antimicrobial Stewardship Programs in Outpatient Settings: A Systematic Review (2014) (31)
Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. (2009) (29)
Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia (2020) (29)
Focused Evidence Review: Psychometric Properties of Patient-Reported Outcome Measures for Chronic Musculoskeletal Pain (2018) (28)
Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians (2020) (26)
Recurrent Nephrolithiasis in Adults: Comparative Effectiveness of Preventive Medical Strategies (2012) (26)
Risk of Bias (2012) (26)
Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects (2002) (24)
SAW PALMETTO EXTRACT FOR TREATMENT OF BENIGNE PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW (1999) (24)
Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment (2012) (23)
Effectiveness of early diagnosis, prevention, and treatment of Clostridium difficile infection (2011) (23)
Botulinum toxin for treatment of urinary incontinence due to detrusor overactivity: a systematic review of effectiveness and adverse effects (2007) (23)
Effectiveness of Family and Caregiver Interventions on Patient Outcomes Among Adults with Cancer or Memory-Related Disorders: A Systematic Review (2013) (21)
Effectiveness of Caregiver Interventions on Patient Outcomes in Adults With Dementia or Alzheimer’s Disease (2015) (21)
Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review (2019) (21)
Management of Insomnia Disorder (2015) (20)
Tamsulosin for benign prostatic hyperplasia. (1997) (20)
Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review. (2020) (19)
WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. (2011) (18)
Cognitive Outcomes After Cardiovascular Procedures in Older Adults: A Systematic Review (2014) (18)
Systematic Review of the Literature on Comparative Effectiveness of Antiviral Treatments for Chronic Hepatitis B Infection (2011) (18)
Comparative Effectiveness of Home-Based Kidney Dialysis Versus In-Center or Other Outpatient Kidney Dialysis Locations – A Systematic Review (2015) (18)
The Effects of Shared Decision Making on Cancer Screening – A Systematic Review (2014) (18)
Provider Types and Outcomes in Obstructive Sleep Apnea Case Finding and Treatment (2018) (17)
5-a-Reductase inhibitors for prostate cancer chemoprevention: An updated Cochrane systematic review (BJU International (2010) 106:10 (1444-1451)) (2011) (17)
Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Review (2016) (16)
Comparative Effectiveness of Clostridium difficile TreatmentsA Systematic Review (2011) (16)
Terazosin for treating symptomatic benign prostatic obstruction (2002) (16)
Doxazosin in the treatment of benign prostatic hypertrophy: an update (2006) (16)
Evidence Review—Social Determinants of Health for Veterans (2018) (15)
Collaborative self-management and behavioral change. (2014) (15)
Terazosin for benign prostatic hyperplasia. (2011) (15)
Prevalence and Severity of Psychiatric Disorders and Suicidal Behavior in Service Members and Veterans With and Without Traumatic Brain Injury: Systematic Review (2020) (15)
Management of stable chronic obstructive pulmonary disease (2007) (14)
A Systematic Review of the Efficacy of Adding Nonexposure Components to Exposure Therapy for Posttraumatic Stress Disorder (2013) (14)
Benefits and Harms of the Mediterranean Diet Compared to Other Diets (2015) (14)
Management of chronic hepatitis B. (2008) (13)
Cernilton for benign prostatic hyperplasia (2011) (13)
Serenoa repens for benign prostatic hyperplasia (Review) (2009) (13)
DISCUSSION AND RECOMMENDATIONS (2011) (12)
Effectiveness and Harms of High-Flow Nasal Oxygen for Acute Respiratory Failure: An Evidence Report for a Clinical Guideline From the American College of Physicians (2021) (12)
Serenoa repens for benign prostatic hyperplasia. (2012) (12)
Diagnosis and Treatment of Erectile Dysfunction (2009) (10)
Antimicrobial Stewardship Programs in Inpatient Settings (2013) (10)
Family Involved Psychosocial Treatments for Adult Mental Health Conditions: A Review of the Evidence (2012) (9)
Chronic Urinary Retention: Comparative Effectiveness and Harms of Treatments (2014) (9)
Treatment for Restless Legs Syndrome (2012) (9)
Effectiveness of statin therapy in adults with coronary heart disease (2004) (8)
Population-Based Assessment of Determining Treatments for Prostate Cancer (2016) (8)
Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review (2019) (6)
Safe and Effective Anticoagulation in the Outpatient Setting: A Systematic Review of the Evidence (2011) (6)
The Comparative Effectiveness, Harms, and Cost of Care Models for the Evaluation and Treatment of Obstructive Sleep Apnea (OSA): A Systematic Review (2016) (6)
Rapid Evidence Review: Measures for Patients with Chronic Musculoskeletal Pain (2017) (6)
Systematic Review: Outcomes by Duration of NPO Status prior to Colonoscopy (2017) (6)
Newer Minimally Invasive Treatment Modalities to Treat Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (2021) (5)
Microwave thermotherapy for benign prostatic obstruction (2003) (5)
RISK OF BIAS CRITERIA (2013) (5)
Pharmacist-Led Chronic Disease Management (2015) (5)
Chronic Kidney Disease Stages 1–3 (2012) (5)
Update Alert: Remdesivir for Adults With COVID-19 (2021) (5)
Colonoscopy Outcomes by Duration of NPO Status Prior to Colonoscopy with Moderate or Deep Sedation (2015) (5)
DATA EXTRACTION FORM (2010) (5)
WITHDRAWN: Cernilton for benign prostatic hyperplasia. (2011) (5)
Relationship of Deployment-related Mild Traumatic Brain Injury to Posttraumatic Stress Disorder, Depressive Disorders, Substance Use Disorders, Suicidal Ideation, and Anxiety Disorders: A Systematic Review (2019) (5)
WITHDRAWN: Terazosin for benign prostatic hyperplasia. (2011) (4)
Effectiveness and harms of mental health treatments in service members and veterans with deployment-related mild traumatic brain injury. (2019) (4)
Total Knee Replacement: Summary (2003) (4)
Chondroitin for osteoarthritis (Review) (2015) (4)
PEER REVIEW COMMENTS/AUTHOR RESPONSES (2012) (4)
List of Acronyms and Abbreviations (2008) (3)
Life Expectancy Calculators (2016) (3)
Beta-sitosterols for benign prostatic hyperplasia (Review) (2011) (3)
Update Alert 2: Remdesivir for Adults With COVID-19 (2021) (3)
Effectiveness and harms of high-flow nasal oxygen (HFNO) for acute respiratory failure: a systematic review protocol (2020) (3)
Enhanced Recovery After Surgery (ERAS) Programs for Patients Undergoing Colorectal Surgery (2017) (3)
The intersection of implementation science and community-based suicide prevention research: Opportunities to advance the field. (2021) (3)
Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia (2020) (2)
Population- and Community-Based Interventions to Prevent Suicide. (2022) (2)
Pharmacologic Therapy for Primary Restless Legs Syndrome (2013) (2)
Table 1, Pharmacologic treatments for Restless Legs Syndrome (2012) (2)
Definitions of Outcomes (2008) (2)
Review: Fidaxomicin is better than vancomycin for clostridium difficile recurrence (2012) (1)
Figure A, Analytic framework for multidisciplinary postacute rehabilitation for TBI in adults (2012) (1)
The Effect of Medical Scribes in Emergency Departments: A Systematic Review. (2021) (1)
Chondroitin for osteoarthritis (Protocol) (2009) (1)
COVID-19 postacute care major organ damage: a systematic review (2022) (1)
Fecal Microbiota Transplantation for Clostridium Difficile Infection: A Systematic Review of the Evidence (2014) (1)
Table 1, Criteria used to classify TBI severity (2012) (1)
Table 12, Summary of Results from Studies of Dental Pain, Urinary Tract Infection, and Sexually Transmitted Infections (2014) (1)
The Assessment and Treatment of Individuals with History of Traumatic Brain Injury and Post-Traumatic Stress Disorder (2009) (1)
Alfuzosin for benign prostatic hyperplasia (2013) (1)
Anticoagulant prophylaxis for hospitalized medical patients. (2007) (1)
Table 13, Mean days to resolution of diarrhea/clinical improvement for vancomycin versus metronidazole (2011) (0)
Figure 22, HBV DNA loss at followup off the drug therapies for chronic hepatitis B by patient pretreatment status, baseline HBeAg positivity, and the proportion of the patients with baseline cirrhosis, the results from individual studies (2008) (0)
Table 7, Outcomes Reported in Studies of Communication Skills Training (2014) (0)
Appendix F. Table 7, International Restless Legs Study Group Rating Scale (IRLS) scores for iron studies (2012) (0)
Appendix G. Table 7, Withdrawals and adverse effects for the dopamine agonist versus levopdopa Part A (2012) (0)
Table 11, Key Elements for Success and Barriers to Implementation (2010) (0)
Secondary Stone Recurrence Outcomes Tables (2012) (0)
Appendix F. Quality Assessment (2009) (0)
ACTIVE RESEARCH FINDINGS (2009) (0)
Appendix F. Table 12, Self-rated quality of sleep for the non-pharmacologic trials (2012) (0)
Table E3, Reported clinical and intermediate outcomes after comparisons of antiviral drugs for chronic hepatitis B (randomized controlled clinical trials) (2008) (0)
Figure 2, Flow diagram of search strategy (2012) (0)
Table 8, Summary of trial comparators for 10 trials of antibiotic treatment of CDI (2011) (0)
Figure 4, Percent Days Abstinent, Differences between BCT and ICBT: Drug Use Disorder Studies Only (2012) (0)
Table E9, Evidence tables of the effects of drug interventions on outcomes among patient subgroups (individual RCTs) (2008) (0)
Appendix F. Table 13, Self-rated quality of life and of sleep for iron trials (2012) (0)
Table 4, Summary of Baseline Characteristics: Biological Skin Equivalents (2012) (0)
Table 12, Strength of evidence for the miscellaneous pharmacologic trials (2012) (0)
Figure 6, Efficacy outcomes for treatment with dopamine agonists: mean change in IRLS rating scale score from baseline (2012) (0)
Appendix E Tables and Figures (2008) (0)
Neuropsychological Test Descriptions (2014) (0)
[Table, Appendix D. Analytic Framework]. (2008) (0)
Table 7, Relative risk of ECG abnormalities in patients with SCI younger vs. older than 65 years of age (2008) (0)
[Figure], Figure 9. Mean levels of LDL cholesterol, SCI studies (2008) (0)
Figure 1, Pathogenesis of CDI (2011) (0)
Table 15, Mean change from baseline for Digit Symbol Test, CABG studies. Higher scores indicate a better result (2014) (0)
FOREST PLOTS FROM POOLED ANALYSES FOR ALCOHOL AND DRUG USE STUDIES (2012) (0)
Figure 5, Overall incidence of CDI from probiotic primary prevention trials (2011) (0)
Table 2, Prevalence of CVD in adults with SCI (2008) (0)
Appendix G. Table 5, Withdrawals and adverse events for acetohydroxamic acid trials (2012) (0)
Figure 68, Mean change from baseline in IIEF-EF score (2009) (0)
Table 23, Mean change from baseline for domains from Altinbas 2011: CAS versus CEA (2014) (0)
Table 23, Trials from ClinicalTrials.gov and other sources (2011) (0)
Appendix F. Figure 2, Efficacy and Harms data for double-blind dopamine agonist trials (2012) (0)
Appendix G. Funnel Plots (2009) (0)
Table 19, Future research recommendations (2011) (0)
Table 4, Effects of drug therapies for chronic hepatitis B on combined outcomes (2008) (0)
[Figure], Figure 2. Flow chart for Question 1 references (2008) (0)
Appendix D, Table 5, Characteristics of Intensive Care Unit Diagnostic Accuracy Studies (2011) (0)
[Table], Evidence Table C5. Intracavernousal Injection Trials (2009) (0)
Appendix A. Exact Search Strings (2008) (0)
Table 3, Significant Risk Factors for Severe Hypoglycemia (2012) (0)
Executive Summary Table 2a, Overview of Prescribing Outcomes - Antimicrobial Stewardship Interventions for Outpatients (2014) (0)
Table 3, Prevalence of CVD in adults with SCI by age and years after injury (2008) (0)
Figure 1a, Percent Days Abstinent, Differences between BCT and ICBT: Studies Not Conducted with Data from Fals-Stewart (2012) (0)
Mean Change from Baseline Tables (2014) (0)
EVIDENCE TABLE: OVERVIEW OF STUDIES FOR KEY QUESTIONS 1 AND 2 (2010) (0)
Figure 2, Flow Diagram – Delirium Screening Studies (2011) (0)
Figure 19, Improved erection (GEQ-Q1): major depressive disorder in remission (2009) (0)
Table C62, Significant variations in proportion of patients treated with watchful waiting (2008) (0)
TABLE 1, Details of published studies evaluated in Key Question 1 (2009) (0)
Table 2, Number of Studies Reporting Each Outcome (and Study-defined Primary Outcome)a (2015) (0)
Figure 51, Withdrawals due to adverse events: patients with diabetes (2009) (0)
Table 4, Prevalence and odds of diabetes in adults with SCI, able bodied veterans, and the general population (2008) (0)
Table 10, Outcomes Reported in Studies of Rapid Antigen Detection Tests, Polymerase Chain Reaction Assay, and C-Reactive Protein (2014) (0)
Table 1, Population Characteristics of Studies Measuring Hypogonadism in Men with Erectile Dysfunction (2009) (0)
Table 5, Study duration and baseline characteristics of patients (means and range) in placebo-controlled studies of dopamine agonists (2012) (0)
Table 12, Association between lactose intolerance or malabsorption and bone fractures (2010) (0)
Figure 5, Relationship Adjustment using Dyadic Adjustment Scale, Difference in Mean Scores between BCT and ICBT: Alcohol Use Disorder Studies Only (2012) (0)
Figure 4, Completion Rate and Adenoma Detection Rate: Outcomes from Observational Studies (2015) (0)
FOREST PLOTS FOR KEY QUESTION #1 (2012) (0)
Figure 2, Analytic framework for CDI diagnostic testing, prevention, and treatment (2011) (0)
Figure 4, Non-adherence to Prescribed Medications, Proportion of Patients (RCTs Only) (2015) (0)
[Table], Comparison of Mild TBI with Moderate and Severe TBI* (2009) (0)
Table B, Summary of postacute rehabilitation programs studied (2012) (0)
Appendix Table D1, Observational studies of lactose intolerance or malabsorption in association with patient outcomes (2010) (0)
Executive Summary Table 1, Overview of Strength of Evidence - Antimicrobial Stewardship Interventions for Outpatients (2014) (0)
Table 6, Overall strength of evidence for individual outcomes in placebo-controlled studies of dopamine agonists (2012) (0)
[Figure], Figure 10. Off treatment comparative effectiveness of combined therapy with pegylated interferon alfa-2a and lamivudine (results from individual studies and pooled analysis) (2008) (0)
Appendix F. Figure 6, Efficacy and Harms data for double-blind Cabergoline (dopamine agonists) vs. levodopa (2012) (0)
Table 12, Age standardized mortality ratios from CVD in adults with SCI compared to the general population (2008) (0)
Figure 8, Relationship Adjustment using Dyadic Adjustment Scale, Difference in Mean Scores between BCT and ICBT: Studies with Female Subjects Only (2012) (0)
Table 4, Prevalence of CVD* according to SCI neurological category (2008) (0)
Listing of Excluded Studies—Cancer Population (2004) (0)
Table E10, Summary tables of the effects of therapies for CHB in patient subpopulations by baseline status of chronic hepatitis B (2008) (0)
COMMON METHODOLOGICAL ERRORS AND RECOMMENDATIONS FOR FUTURE CLINICAL TRIALS OF WOUND HEALING (2012) (0)
Appendix F. Table 6, International Restless Legs Study Group Rating (IRLS) scores for nonpharmacologic studies (2012) (0)
Table 2, Cardiovascular events in adults with chronic traumatic SCI (2008) (0)
Figure 4, Flow Diagram – Delirium ICU Diagnosis Studies (2011) (0)
Appendix F. Data Abstraction Form (2008) (0)
Figure 13, Short-term harms of treatment with dopamine agonists: study withdrawals due to adverse events (2012) (0)
DECISION QUALITY AND DECISION IMPACT MEASURE PATTERNS IN INCLUDED STUDIES (2014) (0)
Table 6, Clinical outcomes after different treatments in patients with localized prostate cancer (2008) (0)
[Figure], Figure 11. Mean levels of triglycerides, SCI studies (2008) (0)
Appendix F. Figure 5, Efficacy and Harms data for double-blind Iron therapy trials (2012) (0)
Baseline Characteristics Summary Tables (2012) (0)
Venous Thromboembolism Prophylaxis (2012) (0)
Table 17, Other outcomes (# subjects / # assessed) for vancomycin versus metronidazole (2011) (0)
Table 4, Components of Multi-Component Interventions for Delirium Prevention (2011) (0)
Table 12, Mean change from baseline for Grooved Pegboard Test (seconds), Carotid artery stenting (CAS) studies. Lower scores indicate a better result (2014) (0)
Table 13, Association between low lactose diets, lactose intolerance or malabsorption, and osteoporosis (2010) (0)
Table 5, Mean change from baseline for Rey Auditory Verbal Learning Test (number of words), CABG studies. Higher scores indicate a better result (2014) (0)
Appendix F. Table 10a, Self-rated quality of sleep for alpha-2-delta ligands trials: Medical Outcomes Scale- Sleep Problems Index II or Pittsburgh Sleep Quality Index (2012) (0)
Table 1, Patient characteristics in studies that reported cardiovascular events in adults with SCI (2008) (0)
[Figure], Figure 18. Adjusted odds ratio of CVD in patients with SCI: Tetraplegia with no functional motor preservation compared to paraplegia and no functional motor preservation (2008) (0)
Figure 7, Efficacy outcomes for treatment with dopamine agonists: change in RLS-specific quality of life (2012) (0)
[Figure], Figure 1. Classic phases in chronic Hepatitis B infection (HBeAg-positive) (2008) (0)
Figure 49, Dyspepsia (all cause) (2009) (0)
Figure 10, Efficacy outcomes for treatment with alpha-2-delta ligands: proportion of patients who reported improved or much improved on the clinician-rated global impressions scale (CGI) (2012) (0)
[Figure], Figure 3. Flow chart for Question 2 references (2008) (0)
Table 8, Goal Attainment - Polypharmacy/High Risk (3 studies) (2015) (0)
Figure 11, Proportion of ulcers healed – Electromagnetic Therapy versus Sham (2012) (0)
[Table, PEER REVIEW COMMENTS/AUTHOR RESPONSES]. (2012) (0)
Figure 30, Improved erection (GEQ-Q1) (2009) (0)
Table 13, Intracavernosal Injection: Improvement in Erections* (2009) (0)
[Figure], Figure 6. Off treatment effectiveness of reverse transcriptase inhibitors compared to placebo (results from individual studies and pooled analysis with random effects model) (2008) (0)
Figure 4b, Primary Diagnostic Accuracy of Store and Forward Studies (2010) (0)
[Figure], Figure 13. HDL cholesterol levels of able-bodied males by age (NHANES) (2008) (0)
Table 15, Sustainability of community integration questionnaire score (2012) (0)
Table 8, Population Characteristics of Studies Measuring Serum LH/FSH Levels in Men with Erectile Dysfunction (2009) (0)
Efficacy and safety of laser prostatectomy techniques for treating symptomatic benign prostatic hyperplasia (2001) (0)
Table 16, All-cause mortality (# subjects / # randomized) for all other standard treatment trials (2011) (0)
FOREST PLOTS FOR STRENGTH OF EVIDENCE ANALYSIS (2014) (0)
Figure 3, Quality of Live Interactive Studies (N=8) (2010) (0)
Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia : A Systematic Review and Meta-analysis (2017) (0)
Table 1, Overview of Therapies for Diabetic Ulcers (2012) (0)
Table 3, Prevalence of Hypogonadism in Men with Erectile Dysfunction (serum free or calculated testosterone) (2009) (0)
Table E6, Levels of viral load, biochemical, or histologic outcomes after antiviral drugs in adults with chronic hepatitis B (2008) (0)
Table 1, Empirically Supported Couple and Family Treatments for Mental Health Conditions (Baucom 1998) (2012) (0)
Executive Summary Table 1, Summary of Outcomes Reported in Included Studies (2015) (0)
Table 2, Summary of Baseline Characteristics: Collagen (2012) (0)
[Table], Family Interventions since 1996 that Improve Outcomes for US Patients with Mental Health (MH) Conditions (2012) (0)
[Table], Evidence Table F4. Apomorphine (sublingual) (2009) (0)
Figure 25, Successful intercourse attempts: patients with hypertension taking anti-hypertensivedrugs (2009) (0)
Appendix D. Reference List of Excluded Studies (2009) (0)
Table 5, Summary of Baseline Characteristics: Platelet-Derived Growth Factor (2012) (0)
[Table], Evidence Table C6. Subcutaneous Treatment Trials (2009) (0)
[Table], Evidence Table C9. Testosterone Treatment of ED (2009) (0)
Description and Characteristics of Included Studies (2016) (0)
[Table], Evidence Table C7. Intra-urethral Suppositories (2009) (0)
Table 3, Studies Reporting Diagnostic Accuracy using Histopathology/Lab Tests as Gold Standard (KQ1a) (See Appendix D for abbreviations) (2010) (0)
Appendix I. Table 3, Cognitive Outcomes Tables: Incident Cognitive Impairment Defined by Composite of Neuropsychological Tests – CAS and CEA (2014) (0)
Appendix G. Table 9, Specific adverse effects for the dopamine agonist versus levodopa Part C (2012) (0)
Table 5, Relative risk of ECG abnormalities in adults with SCI compared to able-bodied controls (2008) (0)
Table 6, Goal Attainment - Dyslipidemia (7 studies) (2015) (0)
STUDY QUALITY TABLES (2012) (0)
Appendix F. Table 5, International Restless Legs Study Group Rating (IRLS) scores for miscellaneous pharmacologic studies (2012) (0)
Figure 2, Analytic framework (2012) (0)
Figure 14, The mean IIEF-Q3 score: Type I-II diabetes (2009) (0)
Figure 5, The mean IIEF-Q4 score (2009) (0)
Table 2, Overview of Outcomes Reported (2015) (0)
Table 3, Toxin gene detection tests compared to immunoassays (2011) (0)
[Figure], Figure 19. Hazard ratio of dying based on ECG abnormality vs. normal ECG among VA users with SCI and able-bodied VA users (2008) (0)
Table 13, Overview of secondary outcomes results (2012) (0)
Study Quality/Risk of Bias Tables (2012) (0)
Table E12, Summary of study IDs meeting eligibility for question 4 (2008) (0)
Table 3, Summary of Baseline Characteristics: Biological Dressings (2012) (0)
Table 15, Summary of Baseline Characteristics: Silver Products (2012) (0)
Table E14, Other baseline factors as predictors of outcomes, and other outcomes (n=3) (2008) (0)
Figure 1, Reference Flow Chart (2010) (0)
Figure 9, HBsAg loss combined with other criteria of resolved hepatitis B at followup off the therapy (results from individual RCTs) (2008) (0)
Table 16, Subcutaneous Injection: Patients with Adverse Events (2009) (0)
Appendix Table D2, Association between low dairy Ca++ intake and bone fractures (2010) (0)
Table 18, Intra-urethral Treatment: Improvement in Erections* (2009) (0)
Tamsulosin for treatment of symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects (2001) (0)
Figure 3, Association between milk intake and history of any fracture (2010) (0)
Table 10, Strength of evidence for productivity outcomes (2012) (0)
Figure 14, Significant effects on HBeAg seroconversion for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model) (2008) (0)
[Figure], Figure 8. Mean levels of total cholesterol, SCI studies (2008) (0)
Hyperplasia : A Systematic Review Saw Palmetto Extracts for Treatment of Benign Prostatic (2000) (0)
Supporting Tables: Efficacy of Psychological Interventions for Insomnia Disorder (2015) (0)
Table 23, Testosterone: Improvement in Sexual Intercourse Outcomes (2009) (0)
Table 7, Summary of risk factors for CDI (2011) (0)
Figure 24, Improved erection (GEQ-Q1): patients with hypertension taking anti-hypertensive drugs (2009) (0)
Figure 5, Clinical Outcomes for Depression Trials (2015) (0)
Table A1, Treatments for chronic urinary retention (2014) (0)
Table 20, Alprostadil (Topical Cream) vs. Placebo: Sexual Encounter Profile (SEP) (2009) (0)
Figure 9, Headache (all cause) (2009) (0)
[Table], Evidence Table C8. Topical Treatments of ED (2009) (0)
Table 17, Strength of Evidence – Advanced Wound Care Therapies for Venous Ulcers (2012) (0)
Figure 21, The mean IIEF-Q4 score: major depressive disorder in remission (2009) (0)
[Figure], Figure 4. Off treatment effectiveness of monotherapy with interferon compared to no treatment (results from individual studies and pooled analysis with random effects model) (2008) (0)
Table 9, Hazard ratio of dying having ECG abnormality vs. normal ECG among patients with SCI and able-bodied veterans (2008) (0)
Table 26, Testosterone Treatment: Patients with Adverse Events (2009) (0)
Figure 19, ALT normalization at followup off the drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model) (2008) (0)
Treatment of acute mountain sickness (1981) (0)
Figure 5, Proportion of Diabetic Ulcers Healed – Silver Products (2012) (0)
Figure 7, Association between genetic polymorphism TT vs. C/C and positive tests for lactose malabsorption, crude odds ratios from two Austrian observational population based studies of genetic screening for osteoporosis (2010) (0)
Table 7, Effects of antiviral drugs on HBeAg-negative patients (relative risk from individual RCTs) (2008) (0)
Table 5, Outcomes Reported in Studies of Guidelines (2014) (0)
Figure 3, Percent Days Heavy Drinking, Differences between BCT and ICBT: Alcohol Use Disorder Studies Only (2012) (0)
Table 6, Subjects withdrawing from treatment and experiencing adverse events from randomized controlled trials (2008) (0)
Flower Pollen Extract and its Effect on the Prostate A systematic review of Cernilton for the treatment of benign prostatic hyperplasia (2017) (0)
Appendix F. Table 2, International Restless Legs Study Group Rating Scale (IRLS) scores for the dopamine agonist studies (2012) (0)
Figure 2, Percent Days Abstinent, Differences between BCT and ICBT: Alcohol Use Disorder Studies Only (2012) (0)
[Figure], Figure 5. Off treatment effectiveness of combined therapy with interferon compared to placebo (results from individual studies and pooled analysis with random effects model) (2008) (0)
Figure 10, Flushing (all cause) (2009) (0)
Figure 6b, Aggregated Diagnostic Accuracy of Store and Forward Studies (2010) (0)
Figure 13, Symptomatic response# of adult lactose malabsorbers to lactose ingested without nutrients other than milk (2010) (0)
Figure 5, Association between milk intake and osteoporotic bone fractures (2010) (0)
Appendix. F. Figure 3, Efficacy and Harms data for double-blind alpha-2-delta ligands trials (2012) (0)
Appendix Table D6, Association between lactose intake and metabolism and bone mineral density (BMD, g/cm2) (2010) (0)
Table E4, Evidence tables of the effects of antiviral drugs on patient outcomes (individual randomized controlled clinical trials) (2008) (0)
Table 18, Summary of study characteristics for blinded LI treatment studies (2010) (0)
Table 14, Sustainability of productivity outcomes (2012) (0)
STUDY SELECTION FORM (2011) (0)
Figure 12, Improved erection (GEQ-Q1): Type I-II diabetes (2009) (0)
Table 24, Testosterone (T) Combined with PDE-5 inhibitors: Improvement in Sexual Intercourse Outcomes (2009) (0)
Appendix F. Table 11, Self-rated quality of life and of quality sleep for the miscellaneous pharmacologic trials (2012) (0)
Appendix F. Table 8, IRLS Remitters (score = 0): Absolute effect per 100 patients (2012) (0)
Figure 65, Improved erection (GAQ-Q) (2009) (0)
Figure 13, Significant relative risk of virological, histological and biochemical outcomes after drug therapies for chronic hepatitis B (results from individual RCT and pooled consistent results using random effects model) (2008) (0)
Table 10, Overall strength of evidence for individual outcomes in placebo-controlled studies of alpha-2-delta ligands (2012) (0)
[Figure], Figure 8. Off treatment comparative effectiveness of combined with interferon or reverse transcriptase inhibitors (results from individual studies and pooled analysis with random effects model) (2008) (0)
Appendix D. Analytic Framework (2008) (0)
Table A, Summary of evidence (2009) (0)
Appendix F. Table 9a, Self-rated quality of sleep for dopamine agonist trials: Medical Outcomes Scale- Sleep Problems Index II (2012) (0)
Table 2, Calcium content in common foods (2010) (0)
Executive Summary Table 2, Strength of Evidence - Advanced Wound Care Therapies for Venous Ulcers (2012) (0)
[Table], Evidence Table C1. Oral Sildenafil (2009) (0)
Table 9, Time to Treatment and Clinic Dermatology Visits Avoided for Teledermatology Studies (KQ3) (2010) (0)
Table 10, Initial clinical cure (# subjects / # randomized) for all other standard treatment trials (2011) (0)
Appendix Table D5, Gains in osteodensitometric values in prepubertal boys consuming low lactose diet (74% of the recommended daily Ca++ intake) after interventions with dairy foods (1,607 vs. 747mg/day of Ca++) (2010) (0)
Figure 6, Time to Complete Healing, Diabetic Ulcers – Negative Pressure Wound Therapy (2012) (0)
Supporting Tables: Efficacy of Pharmacologic Interventions for Chronic Insomnia (2015) (0)
Figure 7, Proportion of Diabetic Ulcers Healed – Hyperbaric Oxygen Therapy (2012) (0)
[Figure], Figure 3. Survival by hepatitis status, modified from Tong, 2006 (2008) (0)
Table 14, Baseline Study Characteristics: Keratinocytes (2012) (0)
Table 9, Initial clinical cure (# subjects / # randomized) for vancomycin versus metronidazole (2011) (0)
Table 13, Strength of evidence for the nonpharmacologic trials (2012) (0)
Supporting Tables: Efficacy of Complementary and Alternative Medicine Interventions for Insomnia Disorder (2015) (0)
Table 8, Outcomes Reported in Studies of Restriction Policies (2014) (0)
Table 16, Strength of evidence for sustainability outcomes (2012) (0)
Stroke/TIA Outcomes Tables (2014) (0)
Figure 20, Combined outcomes at the end of the treatments by baseline ALT levels (individual RCTs) (2008) (0)
Table 1, Recommended calcium intake by age group (2010) (0)
Table 2, Summary of Study Characteristics for Teledermatology Studies (KQ1 and KQ2) (2010) (0)
[Figure], Figure 15. Prevalence of BMI levels by age group (NHANES 1999-2002) (2008) (0)
Appendix E. Additional Acknowledgments (2009) (0)
Table 14, Description of exercise intervention studies with lipid or cardiovascular related outcomes in people with SCI (2008) (0)
Table D1, Operational definitions of treatment options for hepatitis B (2008) (0)
[Figure], Figure 9. Off treatment comparative effectiveness of monotherapy with pegylated interferon alfa-2a compared to lamivudine (results from individual studies and pooled analysis) (2008) (0)
Table 6, Summary of Baseline Characteristics: Platelet Rich Plasma (2012) (0)
[Table, IIEF domains and the scoring]. (2009) (0)
Figure 3, Efficacy outcomes for treatment with dopamine agonists: proportion of study participants who reported greater than 50 percent reduction in mean IRLS score from baseline (2012) (0)
Figure 55, Serious adverse events (all cause) (2009) (0)
Appendix G. Table 5, Adverse effects for the alpha-2-delta ligands trials Part B (2012) (0)
Figure 17, Any adverse events (treatment-related): Type II diabetes (2009) (0)
Figure 21, The effects of lamivudine, 100mg/day compared to placebo at the end of the treatment depending on baseline ALT level (4 lamivudine-controlled Phase III trials) (2008) (0)
Table 19, Occurrence of GI symptoms in randomized trials (2010) (0)
Appendix F. Table 14, Patient global impressions responders (PGI) at end of treatment for dopamine agonist studies (2012) (0)
Table 22, Summary of evidence (2011) (0)
Figure C11, Which therapy offers the best survival to patients with clinically localized prostate cancer? Treatment recommendations by urologists and radiation oncologists (Fowler, 2000) (2008) (0)
[Table], Evidence Table C3. Oral Tadalafil (2009) (0)
RESEARCH HIGHLIGHTS: EBM from the Cochrane Library (2009) (0)
Table 5, (A) Studies of multiple interventions used together to reduce CDI incidence (2011) (0)
PEER REVIEW COMMENTS AND RESPONSES (2011) (0)
Figure 8, Any adverse events (treatment-related) (2009) (0)
Figure 40, Successful intercourse attempts (SEP-Q3) (2009) (0)
Table 9, Summary of study baseline characteristics for alpha-2-delta ligand drugs trials (2012) (0)
Table 5, Overview of included studies (2012) (0)
Table 6, Relative risk of electrocardiogram abnormalities in patients with SCI with intact sympathetic innervation to the heart (injury level T6 and below) compared to impaired sympathetic activity (injury level T5 and above) (2008) (0)
Table 18, Overview of Therapies for Arterial Ulcers, Mixed Lower Extremity Ulcers, and Amputation Wounds (2012) (0)
Table 16, Mean change from baseline for Block Design (raw score), CABG studies. Higher scores indicate a better result (2014) (0)
Appendix G. Table 6a, Specific adverse effects for the alpha-2-delta ligands trials Part C (2012) (0)
Table 1, Summary of diagnostic comparisons in included studies (2011) (0)
Table 1, Mean change from baseline for Trail Making A (time in seconds), CABG studies. Lower scores indicate a better result (2014) (0)
Appendix G. Table 4, Withdrawals and adverse effects for the alpha-2-delta ligands trials Part A (2012) (0)
Table 28, Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (2009) (0)
Table 10, Ulcer Size, Ulcer Duration, and Definitions of Closure: Hyperbaric Oxygen Therapy versus Standard Care/Sham (2012) (0)
Table 20, Probiotic or prebiotic interventions for prevention of initial and recurrent CDI (2011) (0)
Table 2, Effect Sizes for Trials of Quality Improvement Strategies to Improve the Antimicrobial Selection Decision (Ranji 2006, Steinman 2006) (2014) (0)
Appendix F. Table 15, Clinical global impressions (CGI) responders (much-very much improved) at end of treatment for the dopamine agonist studies (2012) (0)
[Table, Key Question 1 - literature search string]. (2008) (0)
Table 7, Prevalence of adult-type hypolactasia genotype (2010) (0)
Table 4, Exclusion criteria (2012) (0)
Table 15, Percent change in osteodensitometric values after administration of dairy products in children consuming low lactose diets (RCTs) (2010) (0)
Table 5, Prevalence of lactose malabsorption by challenge (2010) (0)
Table 10, Serious Adverse Events in Sidenafil vs. Placebo (data from RCTs) (2009) (0)
Table C, Summary and strength of evidence (SOE) of effectiveness and comparative effectiveness of multidisciplinary postacute rehabilitation for TBI (2012) (0)
THERAPY DESCRIPTIONS AND REFERENCES (2012) (0)
Figure 9, Bone mineral content from RCTs of dairy product use in children and adolescents with low lactose diets. Femoral neck (2010) (0)
Appendix G. Table 1, Withdrawals and adverse effects for the dopamine agonist trials Part A (2012) (0)
Table 6, Outcomes Reported in Studies of Delayed Prescribing (2014) (0)
Figure 6, Goal Attainment for Diabetes, Dyslipidemia, Hypertension, and Polypharmacy Studies Based on Primary Outcome (RCTs Only) (2015) (0)
Table 2, Comparisons of immunoassays for toxins A and B (2011) (0)
[Table, Technical Expert Panel Members and Affiliation]. (2011) (0)
Supporting Tables: Comparative Effectiveness of Trials Across Intervention Types (2015) (0)
Table 8, Summary of Baseline Characteristics: Negative Pressure Wound Therapy (2012) (0)
Figure 69, Mean per-patient percent absolute change from baseline in SEP-Q2 (2009) (0)
Figure 1, Analytic Framework for the Diagnosis and Treatment of Erectile Dysfunction (2009) (0)
Supporting Tables and Figures: Anticholinergics (2016) (0)
Appendix B. Data Assessment, Data Abstraction and Quality Assessment Forms (2009) (0)
[Table], Reviewer Comments Export (2015) (0)
PEER REVIEWER COMMENTS (2009) (0)
Supporting Tables: Mirabegron (2016) (0)
[Table], Evidence Table C10. Off Label Treatments (2009) (0)
[Table, Key Questions 2–4 - literature search strings]. (2008) (0)
Figure 3, Flow Diagram – Delirium Prevention Studies (2011) (0)
Table 5, Goal Attainment - Diabetes Mellitus (24 studies) (2015) (0)
Table 3, Evidence Summaries for the Randomized Pharmacologic Delirium Studies: Incidence of Delirium (2011) (0)
Figure 6, Effects of active treatments compared to placebo on HBsAg loss at followup off the treatment (results from individual RCTs) (2008) (0)
Table 19, Intra-urethral Treatment: Patients with Adverse Events (2009) (0)
Evidence Tables and Figures (2008) (0)
Appendix F. Table 9b, Self-rated quality of daytime sleepiness for dopamine agonist trials: Epworth Sleepiness Scale (2012) (0)
Table 15, Diet and pharmacologic therapy studies for prevention and/or treatment of carbohydrate and lipid metabolism disorders in people with spinal cord injury and disease (2008) (0)
RISK OF BIAS TABLES (2015) (0)
Table 7, Goal Attainment - Hypertension (15 studies) (2015) (0)
Safe and Effective Anticoagulation in the Outpatient Setting (2011) (0)
Baseline Characteristics Tables (2012) (0)
Table 9, Characteristics of included studies (2008) (0)
[Figure], Figure 5. Diabetes prevalence, SCI vs. Control (2008) (0)
Figure 43, IIEF-EF ≥ 26 at follow up (weeks 10–12) (2009) (0)
Table 8, Effects of antiviral drugs for chronic hepatitis B on off treatment outcomes in patient subpopulations (2008) (0)
Figure 2, Quality of Store and Forward Studies (N=41) (2010) (0)
Figure 23, HBeAg loss and seroconversion at followup off drug therapies for chronic hepatitis B by patient pretreatment status, baseline HBeAg positivity, and the proportion of the patients with baseline cirrhosis, results from individual studies (2008) (0)
Figure 14, Short-term harms of treatment with alpha-2-delta ligands: any study withdrawals (2012) (0)
Table E8, Number of subjects with laboratory abnormalities from RCTS (2008) (0)
Figure 3, Comparative effectiveness of interferon alfa-2b and reverse transcriptase inhibitors on mortality, results from individual randomized controlled clinical trials (2008) (0)
Table 2, Prevalence of Hypogonadism in Men with Erectile Dysfunction (serum total testosterone) (2009) (0)
Efficacy of Long-Term Osteoporosis Drug Treatment (2019) (0)
[Figure], Figure 6. Prevalence of diagnosed diabetes, undiagnosed diabetes, and impaired fasting glucose in men (NHANES 1999-2002) (2008) (0)
Table 14, Mean days to resolution of diarrhea/clinical improvement for all other standard treatment trials (2011) (0)
Figure 28, Dyspepsia (treatment-related): patients with hypertension taking anti-hypertensive drugs (2009) (0)
Cognitive Outcomes Tables: Individual Neuropsychological Tests/Cognitive Domains (2014) (0)
Table 12, Intracavernosal Injection: Sexual Intercourse Success (2009) (0)
Figure 9, Proportion of Venous Ulcers Healed - Keratinocytes versus Standard Care (2012) (0)
Table E1, Evidence table: Observational studies of the natural history of chronic hepatitis B in adults (2008) (0)
Table 6, Percent of all deaths from CVD among adults with SCI (2008) (0)
Table 3, Prevalence of lactose intolerance symptoms following challenge (2010) (0)
[Figure], Figure 17. Odds ratios* of cardiovascular outcomes in VA users with SCI and diabetes vs. SCI but no diabetes (2008) (0)
Figure 5, Incidence of Delirium, Randomized Pharmacologic Trials (2011) (0)
CRITERIA USED IN QUALITY ASSESSMENT OF NON-RANDOMIZED STUDIES (2012) (0)
Figure 42, Improved erection without Carson 2004 (GAQ-Q1) (2009) (0)
Table 9, Association between low lactose diets and bone fractures (2010) (0)
Table 2, Treatments of hepatitis B: Overview of randomized controlled trials (2008) (0)
Figure 16, Significant effects on combined virological and biochemical outcomes at follow up after drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model) (2008) (0)
Withdrawals and Adverse Events Tables (2012) (0)
Table 3, Descriptions of secondary outcomes scales (2012) (0)
Figure 1, Flow Chart for Key Questions (2008) (0)
Table 4, Prevalence of Hypogonadism in Men with Erectile Dysfunction (serum bioavailable testosterone) (2009) (0)
Appendix F. Table 1, IRLS responders (≥ 50% score reduction) at end of treatment for the dopamine agonist studies (2012) (0)
Table 25, Testosterone Treatment: Improvement in Erections (2009) (0)
Table 2, Incidence of Delirium - Pharmacologic Prevention Studies (2011) (0)
[Figure], Figure 2. Hepatitis B analytic framework (2008) (0)
Table 3, Goal Attainment - Cardiovascular Diseasesa (6 studies) (2015) (0)
Table 17, Effect of increased dairy intake on bone health in young and pre-menopausal women consuming low lactose diets (results from individual RCTs) (2010) (0)
Table 13, Description of exercise intervention studies with carbohydrate related outcomes in people with SC (2008) (0)
Table 2, Methods of assessment (2012) (0)
Future Research Needs (2014) (0)
ParticipationAfterMultidisciplinary Rehabilitation forModerate to Severe Traumatic Brain Injury in Adults: A Systematic Review (2013) (0)
Cognitive Outcomes Tables: Clinically Diagnosed Cognitive Impairment (2014) (0)
Table 15, All-cause mortality (# subjects / # randomized) for vancomycin versus metronidazole (2011) (0)
Table 4, Studies for Reporting Diagnostic Concordance between Teledermatology and Usual Care (In-Person Dermatology) (KQ1b)* (2010) (0)
Figure 4, Proportion of Diabetic Ulcers Healed – Platelet-Derived Growth Factor versus Comparator (2012) (0)
[Table], Diagnostic Accuracy, Diagnostic Concordance, Management Accuracy, Management Concordance (2010) (0)
Table 16, Ulcer Size, Ulcer Duration, and Definitions of Closure: Electromagnetic Therapy (2012) (0)
Appendix F. Figure 1, IRLS Remitters analyses (2012) (0)
Table 8, Patient Satisfaction and Patient Preference for Teledermatology Studies (KQ3) (2010) (0)
Figure 17, Patients with ≥1 adverse effect, alpha-2-delta ligands trials (2012) (0)
Figure 2, Effects of interferon alfa-2b and reverse transcriptase inhibitors on clinical outcomes compared to placebo or no active treatment—Relative risk from four individual RCTs (2008) (0)
Figure 2, Proportion of Diabetic Ulcers Healed - Biological Skin Equivalent (Dermagraft) versus Standard Care (2012) (0)
Table 9, Summary of Baseline Characteristic: Hyperbaric Oxygen Therapy versus Standard Care/Sham (2012) (0)
Figure 2, Reference flow diagram (2010) (0)
Figure 32, Flushing (all cause) (2009) (0)
Figure 4, Comparative effectiveness of active drugs on clinical outcomes, results from individual RCTs (2008) (0)
Appendix G. Table 3, Specific adverse effects for the dopamine agonist trials Part C (2012) (0)
Appendix F. Table 3, International Restless Legs Study Group Rating Scale (IRLS) scores for alpha-2-delta ligands studies (2012) (0)
Table 10, Age standardized mortality ratios in adults with chronic SCI compared to the general population (no adjustment for other confounding factors) (2008) (0)
Technical Expert Panel Members and Affiliation (2011) (0)
Figure 7, Comparative effectiveness of active treatments on HBsAg loss at the end of the treatments (results from individual RCTs) (2008) (0)
[Figure], Figure 7. Weighted mean differences in lipid levels (mg/dL): Spinal cord injured subjects vs. controls (2008) (0)
Figure 14, Percentage of subjects reporting abdominal pain (2010) (0)
Figure 60, Absolute mean change in IIEF-EF score (2009) (0)
Table 4, Prevention interventions (2011) (0)
Table 13, Baseline Study Characteristics: Biological Skin Equivalents (2012) (0)
Table 1, Prevalence of metabolic syndromes, diabetes, glucose, lipid abnormalities, and BMI in adults with chronic posttraumatic SCI (2008) (0)
Appendix F: Conceptual Definition of Outcomes (2008) (0)
Table 14, Strength of evidence for iron trials for the treatment of secondary RLS (2012) (0)
Appendix D, Table 3, Characteristics of Non-Pharmacologic or Mixed Treatments Prevention Studies (2011) (0)
Does Tiotropium Reduce Hospitalizations in Chronic Obstructive Pulmonary Disease (2008) (0)
Table E5, Summary tables of the effects of drug therapies for chronic hepatitis B on outcomes (2008) (0)
Figure 41, Improved erection (GAQ-Q1) (2009) (0)
Figure 1, Literature Flow Chart (2015) (0)
Table 7, Odds ratios of diabetes or CVD in adults with SCI compared to able bodied (2008) (0)
Flower Pollen Extract and its Effect on the Prostate Phytotherapy for benign prostatic hyperplasia (2017) (0)
Figure 44, Any adverse events (all cause) (2009) (0)
Figure 7, Percent Days Abstinent, Differences between BCT and ICBT: Studies with Female Subjects Only (2012) (0)
Future Research Recommendations (2012) (0)
FecalMicrobiota Transplantation for Clostridiumdifficile Infection A Systematic Review (2015) (0)
Supporting Tables and Figures: Silodosin (2016) (0)
Table 1, Factors associated with increased risk of selected outcomes in adults with chronic hepatitis B (2008) (0)
Appendix G. Table 10, Withdrawals and adverse effects for the iron trials (secondary RLS) (2012) (0)
Table 19, Nonstandard intervention for treatment of initial and recurrent CDI (2011) (0)
Figure 58, Flushing (all cause) (2009) (0)
Figure 12, Short-term harms of treatment with dopamine agonists: any study withdrawal (2012) (0)
Table 11, Studies Conducted in VA Medical Centers (2014) (0)
Table 9, Mean change from baseline for Trail Making B (time in seconds), Carotid artery stenting (CAS) studies. Lower scores indicate a better result (2014) (0)
Table 6, Studies Reporting Management Concordance between Teledermatology and Usual Care (In-Person Dermatology) (KQ2b) (2010) (0)
Appendix D, Table 1, Characteristics of Pharmacologic Prevention Studies (2011) (0)
Table 21, Summary of case studies/series and potential harms of nonstandard interventions for CDI (2011) (0)
Figure 1, The International Classification of Function, Disability, and Health (ICF) (2012) (0)
Primary Stone Recurrence Outcomes Tables (2012) (0)
CRITERIA USED IN QUALITY ASSESSMENT (2013) (0)
Evidence Tables and Other Supporting Tables and Figures (2012) (0)
[Table, IIEF-5 scoring system]. (2009) (0)
Table 9, Strength of Evidencea (2015) (0)
Cognitive Outcomes Tables: Incident Cognitive Impairment Defined by Composite of Neuropsychological Tests (2014) (0)
ICE volume 36 issue 2 Cover and Front matter (2015) (0)
Appendix F. Table 4, International Restless Legs Study Group Rating Scale (IRLS) scores for the cabergoline studies (2012) (0)
[Table, Appendix F: Conceptual Definition of Outcomes]. (2008) (0)
Appendix D, Table 2, Primary Prevention Outcomes of Pharmacologic Studies (2011) (0)
Chronic Urinary Retention (2014) (0)
Table E7, Number of subjects experiencing adverse events from RCTs (2008) (0)
Sample Abstraction Forms (2008) (0)
Figure 8, Efficacy outcomes for treatment with dopamine agonists: change in sleep (MOS) scores (2012) (0)
Figure 7b, Management Concordance of Live Interactive Studies (2010) (0)
Table 10, Teledermatology Studies Reporting Cost Outcomes (KQ4) (2010) (0)
Table 3, Prevalence of cardiovascular symptoms* and hypertension depending on level on injury (2008) (0)
Table 5, Mortality from CVD in adults with SCI (2008) (0)
Table 2, Primary outcome scales measuring community integration (2012) (0)
Table 11, Community integration questionnaire (2012) (0)
Table 9, Outcomes Reported in Studies of Clinical Decision Support (2014) (0)
Supporting Tables and Figures: PDE-5 Inhibitors (2016) (0)
Figure 23, The mean IIEF-Q4 score: patients with hypertension taking anti-hypertensive drugs (2009) (0)
USPSTF RECOMMENDATIONS FOR SCREENING FOR SEXUALLY TRANSMITTED INFECTIONS IN WOMEN (2013) (0)
Table 1, Summary of Included Studies (2015) (0)
Appendix D, Table 4, Primary Prevention Outcomes of Non-Pharmacologic or Mixed Studies (2011) (0)
Figure 39, Successful intercourse attempts (SEP-Q2) (2009) (0)
Table 8, Summary of study population characteristics (primary outcome studies with low of moderate risk of bias) (2012) (0)
Table 7, Overview of primary outcomes with strength of evidence (2012) (0)
Table 7, Adverse Events and Mortality – Prevention Studies (2011) (0)
Figure 3, The mean IIEF “EF domain” score (2009) (0)
Analytical Framework and Search Strategies (2016) (0)
Figure 6, Association between dairy calcium intake (mg/day) and bone fractures (2010) (0)
References to Appendixes (2012) (0)
Figure 15, Short-term harms of treatment with alpha-2-delta ligands: study withdrawals due to adverse events (2012) (0)
Table 3, Outcomes Reported in Studies of Provider and/or Patient Education (2014) (0)
Table 4, Outcomes Reported in Studies of Provider Feedback (2014) (0)
Figure 8, Proportion of Venous Ulcers Healed - Biological Skin Equivalent (Dermagraft) versus Compression Bandage (2012) (0)
[Table, SEARCH STRATEGY]. (2010) (0)
Table 6, Mean change from baseline for Rey Auditory Verbal Learning Test (number of words), Carotid artery stenting (CAS) studies. Higher scores indicate a better result (2014) (0)
Figure 46, Serious adverse events (2009) (0)
Appendix Table D7, Association between lactose intake and metabolism and bone density (BD) (2010) (0)
Table 5, Population Characteristics of Studies Measuring Hyperprolactinemia in Men with Erectile Dysfunction (2009) (0)
Appendix I. List of Unobtained Articles (2009) (0)
Table 4, Mean change from baseline for Verbal Fluency, CABG studies. Higher scores indicate a better result (2014) (0)
[Table, Overall ranking of evidence]. (2010) (0)
Figure 63, Absolute mean change from baseline in IIEF-EF score (2009) (0)
Table 11, Clinical recurrence: # subjects / # initially cured (percent) for vancomycin versus metronidazole (2011) (0)
Table 11, Strength of Evidence - Advanced Wound Care Therapies for Diabetic Ulcers (2012) (0)
Figure 9, Efficacy outcomes for treatment with alpha-2-delta ligands: IRLS responders (≥50% scale score reduction) (2012) (0)
Executive Summary Table 2b, Overview of Patient Outcomes - Antimicrobial Stewardship Interventions for Outpatients (2014) (0)
Figure 10, Proportion of Venous Ulcers Healed – Silver Products (2012) (0)
Table 17, Intra-urethral Treatment: Sexual Intercourse (2009) (0)
Table E16, Completed unpublished RCTs in patients with chronic hepatitis B (2008) (0)
Table 1, Summary of Baseline Characteristics (2015) (0)
Table 8, Responders to treatment, Clinician-rated global impressions (CGI) responders: participants who reported improved or much improved: absolute effect per 100 patients (2012) (0)
Figure 16, Patients with ≥1 adverse effect, dopamine agonist trials (2012) (0)
Table 4, Goal Attainment - Chronic Kidney Disease (4 studies) (2015) (0)
Figure 2, Minimum Time from End of Bowel Preparation to Procedure (Blue Lines) or Time Before Procedure when Liquids were Stopped (Red Lines) (2015) (0)
Table 27, Miscellaneous Treatments: Efficacy and Adverse Events (2009) (0)
Table 8, Diabetes management and diabetes complications in VA users with SCI, in VA users without SCI, and non-VA user general population without SCI (2008) (0)
Figure 26, Any adverse event (all cause): patients with hypertension taking anti-hypertensive drugs (2009) (0)
Table 20, Mean change from baseline for Mini Mental State Exam, CEA studies. Higher scores indicate a better result (2014) (0)
Appendix F. Figure 8, Funnel plot for Mean change in IRLS total score from baseline (2012) (0)
Table 11, Association between genetic polymorphism and bone fractures (2010) (0)
Figure 3, Completion Rate, Adenoma Detection Rate, and Diagnostic Yield: Outcomes from Randomized Controlled Trials (2015) (0)
Figure 3, Supplemental prevention framework (2011) (0)
Table 11, Mean change from baseline for Grooved Pegboard Test (seconds), CABG studies. Lower scores indicate a better result (2014) (0)
Table 9, Productivity outcomes (2012) (0)
Table 6, Characteristics of studied interventions (2012) (0)
Table 21, Mean change from baseline for the Montreal Cognitive Assessment, CEA studies. Higher scores indicate a better result (2014) (0)
Table 8, Outcomes – Intensive Care Unit Diagnostic Accuracy Studies (2011) (0)
Figure 1, Literature flow diagram (2011) (0)
Figure 4, Association between milk intake and hip fracture (2010) (0)
[Figure], Figure 14. Mean BMI, SCI, and Control (2008) (0)
Appendix G. Table 2, Adverse effects for the dopamine agonist trials Part B (2012) (0)
Table 5, Incidence of Delirium - Non-Pharmacologic or Mixed Treatments Prevention Studies (2011) (0)
Figure 5, Efficacy outcomes for treatment with dopamine agonists: proportion of study participants who reported improved or much improved on patient-rated global impressions scale (PGI) (2012) (0)
Table 5, Absolute risk difference in tested nonclinical outcomes after antiviral drugs for chronic hepatitis B in adults (2008) (0)
[Table], Evidence Table C2. Oral Vardenafil (2009) (0)
Table 12, Clinical recurrence: # subjects / # initially cured (percent) for all other standard treatment trials (2011) (0)
Table 17, Mean change from baseline for Boston Naming Test or Vocabulary WAIS III, CABG studies. Higher scores indicate a better result (2014) (0)
Table 1, Summary of Study Baseline Characteristics for Delirium Prevention Studies (2011) (0)
[Figure], Figure 12. Total cholesterol, LDL-C and triglyceride levels of able-bodied males by age (NHANES) (2008) (0)
Figure 5a, Aggregated Diagnostic Concordance of Store and Forward Studies (2010) (0)
Risk of Bias Assessment Instrument and Instructions (2016) (0)
Figure 5b, Primary Diagnostic Concordance of Store and Forward Studies (2010) (0)
Table E2, Evidence table: Randomized controlled trials for treatment of hepatitis B (2008) (0)
Appendix F. Figure 7, Fixed-dose analyses of harms: Dopamine agonists (2012) (0)
Figure 11, Visual disturbances (all cause) (2009) (0)
Table 18, Outcomes for all standard treatment trials (2011) (0)
Appendix H. Instruments Used in the Assessment of Treatment Outcomes (2009) (0)
Appendix F. Table 10b, Self-rated quality of daytime sleepiness for alpha-2-delta ligands trials: Epworth Sleepiness (2012) (0)
Figure 27, Headache (treatment-related): patients with hypertension taking anti-hypertensive drugs (2009) (0)
Table 14, Intracavernosal Injection: Patients with Adverse Events (2009) (0)
Risk of Bias and Quality (2014) (0)
Table E13, Evidence table of the studies that examined the association between changes in intermediate outcomes to predict treatment effectiveness (n=4) (2008) (0)
Table 12, Overview of Therapies for Venous Ulcers (2012) (0)
Appendix D. Table 1, Secondary outcomes (2012) (0)
Appendix F. Figure 4, Efficacy and Harms data for double-blind Cabergoline trials (2012) (0)
Table 1, Effect Sizes for Trials of Quality Improvement Strategies to Improve the Treatment Decision (Ranji 2008) (2014) (0)
Table C67, Significant differences in age adjusted rate/100,000 male population (pooled analysis) (2008) (0)
Table 12, Strength of evidence for the primary TBI studies: CIQ (2012) (0)
Appendix B. Table 1, Risk of Bias for Individual Studies (2012) (0)
[Figure], Figure 4. Flow chart for Question 3a references (exercise/physical activity interventions) (2008) (0)
Table 7, Responders to treatment, International Restless Legs Syndrome Study Group Rating Scale responders (≥50% score reduction): Absolute effect per 100 patients (2012) (0)
Appendix A. Search Strategies (2009) (0)

This paper list is powered by the following services:

Roderick Macdonald's Academic­Influence.com Rankings

Roderick Macdonald's Degrees

Why Is Roderick Macdonald Influential?

Roderick Macdonald's Published Works

Published Works

Roderick Macdonald's AcademicInfluence.com Rankings